Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi SA is currently conducting a clinical study titled ‘Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO).’ The study aims to assess the efficacy and safety of Dupilumab over a 24-week period in adults suffering from CPUO, a condition characterized by severe itching without a known cause. This study is significant as it explores a potential treatment for a condition that lacks effective therapies.
The intervention being tested is Dupilumab, an experimental drug administered subcutaneously every two weeks. It is used alongside a non-sedative antihistamine and a moisturizer to manage symptoms of CPUO. The purpose of Dupilumab is to reduce the severity of pruritus in affected individuals.
The study is designed as an interventional, randomized, parallel-group trial with a quadruple masking approach. This means that participants, care providers, investigators, and outcomes assessors are all unaware of which participants are receiving the actual drug versus a placebo. The primary goal of the study is to evaluate the treatment’s effectiveness.
The study began on February 15, 2022, and is currently recruiting participants. The primary completion date is yet to be announced, but the last update was submitted on August 19, 2025. These dates are crucial as they provide a timeline for when results might become available, impacting future treatment options and market dynamics.
The ongoing study could significantly impact Sanofi’s stock performance and investor sentiment, especially if Dupilumab proves effective. Success in this trial could position Sanofi as a leader in treating CPUO, potentially influencing the competitive landscape in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.